This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

5 Nov 2010

Coronado Biosciences finishes funding, fills executive seats

Coronado Biosciences has completed a financing series worth $21.6 million.

Coronado Biosciences, a New York-based company focused on oncology drug development, has completed a financing series worth $21.6 million. The funds will be used to develop its acute myelogeous leukemia drug, CNDO-109. The company also announced that Glenn Cooper (executive chairman and acting CEO), Eric Rowinsky (vice chairman) and Gary Gemignani (executive VP, COO and CFO) have joined the company.

Related News